Please check your internet connection and try again.
# Acetylcysteine
## Overview
Acetylcysteine is a mucolytic agent that breaks disulfide bonds in mucus, decreasing its viscosity. It also acts as an antidote for acetaminophen overdose by replenishing hepatic glutathione stores.
## Primary Indications
* **Acetaminophen overdose:** To prevent or reduce liver toxicity.
* **Mucolytic:** To thin respiratory secretions in conditions like cystic fibrosis, chronic bronchitis, and pneumonia.
## Adult Dosing
**Acetaminophen Overdose:**
* **IV Protocol (preferred for initial treatment):** Typically a 3-bag infusion.
* **Loading Dose:** 150 mg/kg IV over 1 hour.
* **Second Infusion:** 50 mg/kg IV over the next 1 hour (may be given concurrently with loading dose completion).
* **Third Infusion:** 100 mg/kg IV over the next 16 hours.
* *Note:* Maximum dose can be high and depends on the severity of overdose and patient weight. Specific protocol adherence is critical.
* **Oral Protocol (alternative, generally less preferred due to nausea/vomiting):**
* **Loading Dose:** 140 mg/kg PO.
* **Subsequent Doses:** 70 mg/kg PO every 4 hours for 17 doses (total of 18 doses).
* *Note:* Antiemetics are often required.
**Mucolytic:**
* **Inhalation:** 10% solution: 3-5 mL nebulized every 6-8 hours. 20% solution: 3-5 mL nebulized every 6-8 hours.
* **Oral (less common):** 200 mg to 600 mg orally 2-3 times daily.
## Pediatric Dosing
**Acetaminophen Overdose (IV Protocol):**
* Dosing is the same as adults: 150 mg/kg IV over 1 hour, then 50 mg/kg IV over 1 hour, then 100 mg/kg IV over 16 hours.
* *Note:* Consider lower volumes for very small children to avoid fluid overload. Specific protocol adherence is critical.
**Mucolytic:**
* **Inhalation:**
* < 4 years: 1-2 mL of 10% or 20% solution nebulized every 6-8 hours.
* > 4 years: 3-5 mL of 10% or 20% solution nebulized every 6-8 hours.
* **Oral:** 50 mg/kg to 100 mg/kg orally 2-3 times daily.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No specific dose adjustments are typically required, but caution is advised, especially in severe impairment. Monitor for adverse effects.
## Contraindications
* Known hypersensitivity to acetylcysteine.
* Acute bronchospasm (inhalation).
## Adverse Effects
* **IV Acetaminophen Antidote:** Anaphylactoid reactions (rash, urticaria, pruritus, angioedema, bronchospasm, dyspnea, hypotension) are common, particularly during the initial loading dose. Nausea and vomiting are also frequent.
* **Inhalation:** Bronchospasm, stomatitis, rhinorrhea, nausea.
* **Oral:** Nausea, vomiting, diarrhea, rash.
## Key Drug Interactions
* **Activated Charcoal:** May decrease the absorption of oral acetylcysteine. Administer acetylcysteine at least 1 hour after activated charcoal.
* **Nitroglycerin:** Potential for additive hypotension.
## Monitoring
* **Acetaminophen Overdose:**
* Acetaminophen and salicylate levels.
* Liver function tests (AST, ALT, bilirubin, INR).
* Renal function.
* Glucose.
* Electrolytes.
* Signs and symptoms of anaphylactoid reaction.
* **Mucolytic:**
* Respiratory status (breath sounds, work of breathing, oxygen saturation).
* Effectiveness in thinning secretions.
* Signs of bronchospasm.
## Clinical Pearls
* For IV administration in acetaminophen overdose, it is crucial to follow a specific institutional protocol. If a patient vomits the initial dose, it may need to be re-administered, often with an antiemetic.
* Anaphylactoid reactions to IV acetylcysteine are usually manageable with antihistamines and do not necessitate immediate discontinuation of the antidote, as the risk of hepatotoxicity from untreated acetaminophen overdose is higher.
* The smell of acetylcysteine is characteristically unpleasant (sulfurous).
* When used as a mucolytic, it is most effective when inhaled.
***
**Disclaimer:** This information is intended for healthcare professionals. Always verify current prescribing information and consult with a pharmacist or physician before making any treatment decisions. Dosing and protocols may vary based on institutional guidelines and individual patient factors.